Abstract:The extracellular microenvironment of the brain contains numerous biological redox agents, including ascorbate, glutathione, cysteine and homocysteine. During ischemia/reperfusion, aging or neurological disease, extracellular levels of reductants can increase dramatically owing to dysregulated homeostasis. The extracellular concentrations of transition metals such as copper and iron are also substantially elevated during aging and in some neurodegenerative disorders. Increases in the extracellular redox capacity can potentially generate neurotoxic free radicals from reduction of Cu(II) or Fe(III), resulting in neuronal cell death. To investigate this in vitro, the effects of extracellular reductants (ascorbate, glutathione, cysteine, homocysteine or methionine) on primary cortical neurons was examined. All redox agents except methionine induced widespread neuronal oxidative stress and subsequent cell death at concentrations occurring in normal conditions or during neurological insults. This neurotoxicity was totally dependent on trace Cu (≥0.4 μM) already present in the culture medium and did not require addition of exogenous Cu. Toxicity involved generation of Cu(I) and H2O2, while other trace metals did not induce toxicity. Surprisingly, administration of Fe(II) or Fe(III) (≥2.5 μM) completely abrogated reductant-mediated neurotoxicity. The potent protective activity of Fe correlated with Fe inhibiting reductant-mediated Cu(I) and H2O2 generation in cell-free assays and reduced cellular Cu uptake by neurons. This demonstrates a novel role for Fe in blocking Cu-mediated neurotoxicity in a high reducing environment. A possible pathogenic consequence for these phenomena was demonstrated by abrogation of Fe neuroprotection after pre-exposure of cultures to the Alzheimer’s amyloid beta peptide (Aβ). The loss of Fe neuroprotection against reductant toxicity was greater after treatment with human Aβ1–42 than with human Aβ1–40 or rodent Aβ1–42, consistent with the central role of Aβ1–42 in Alzheimer’s disease. These findings have important implications for trace biometal interactions and free radical-mediated damage during neurodegenerative illnesses such as Alzheimer’s disease and old-age dementia.

Iron Enhances the Neurotoxicity of Amyloid β

Iron Enhances The Neurotoxicity Of Amyloid Beta

Iron Accumulation And Dna Damage In A Pig Model Of Intracerebral Hemorrhage

The effect of iron on oxidative injury after cerebral hemorrhage

Induction of autophagic cell death in the rat brain caused by iron.

Red blood cell lysis and brain tissue-type transglutaminase upregulation in a hippocampal model of intracerebral hemorrhage.

Intracerebral Hemorrhage in the Iron-Deficient Rat

High Dietary Iron Disrupts Iron Homeostasis And Induces Amyloid-Beta And Phospho-Tau Expression In The Hippocampus Of Adult Wild-Type And App/Ps1 Transgenic Mice

Deferoxamine Reduces Amyloid-Beta Peptides Genesis and Alleviates Neural Apoptosis after Traumatic Brain Injury

Iron and Alzheimer’s Disease: From Pathogenesis to Therapeutic Implications

Thrombin preconditioning reduces iron-induced brain swelling and brain atrophy.

The Correlation Between Accumulation of Amyloid Beta with Enhanced Neuroinflammation and Cognitive Impairment after Intraventricular Hemorrhage

Iron associated lipid peroxidation in Alzheimers disease is increased in lipid rafts with decreased ferroptosis suppressors, tested by chelation in mice

Hepcidin Overexpression in Astrocytes Alters Brain Iron Metabolism and Protects Against Amyloid-Β Induced Brain Damage in Mice

Iron Inhibits Neurotoxicity Induced by Trace Copper and Biological Reductants

Iron Dyshomeostasis Induces Binding of APP to BACE1 for Amyloid Pathology, and Impairs APP/Fpn1 Complex in Microglia: Implication in Pathogenesis of Cerebral Microbleeds

Iron Toxicity in Mice with Collagenase-Induced Intracerebral Hemorrhage

Iron Reduces the Propagation of Pathological -Synuclein an Editorial Highlight for "brain Iron Enrichment Attenuates -Synuclein Spreading after Injection of Preformed Fibrils"

β-Amyloid peptide increases levels of iron content and oxidative stress in human cell and Caenorhabditis elegans models of Alzheimer disease.

Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease.